Global Analysis of Quetiapine (CAS 111974-69-7) Market Size, Growth and Forecast
Report ID : 1356969 | Published : August 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Quetiapine (CAS 111974-69-7) Market is categorized based on Formulation Type (Tablets, Injectables, Oral Solutions) and End User (Hospitals, Clinics, Homecare Settings) and Indication (Schizophrenia, Bipolar Disorder, Major Depressive Disorder) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
With a valuation of USD 1.5 billion in 2023, the Quetiapine (CAS 111974-69-7) Market is expected to reach USD 2.8 billion by 2033, growing at a CAGR of 6.5% from 2024 onwards. The report encompasses various segments and analyzes the trends and factors significantly impacting the market.
The Quetiapine market is witnessing strong growth as mental health disorders, including schizophrenia, bipolar disorder, and major depressive disorder, are on the rise. Quetiapine, a second-generation atypical antipsychotic, has been increasingly used over the years in the healthcare domain due to its effectiveness in addressing the aforementioned sophisticated disorders. Quetiapine, with the chemical structure of CAS 111974-69-7, stands out from other antipsychotics due to its distinctive pharmacological properties which provides additonal therapeutic options for psychiatry.
The global focus on mental health as a crucial component of overall well-being is propelling the demand for efficient intervention strategies. This spike is accompanied by a shift in attitude toward mental disorders, reduced stigma surrounding the need for care, and modern advancements in drug formulations. Market players are highly focused on research and development arms for increasing the effectiveness of Quetiapine while reducing the negative side effects likely to broaden its market potential. In addition, the entry of generic substitutes is expected to intensify competition, with price and access frameworks altering for patients.
Our complete analysis of the Quetiapine market captures primary market trends, competition, and analyzes possible growth avenues for comprehensive understanding. Understanding the intricacies of this industry allows stakeholders to make strategic decisions in this increasingly complex market, ultimately improving patient outcomes.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | AstraZeneca, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, Mylan N.V., Hikma Pharmaceuticals, Lupin Pharmaceuticals, Zydus Cadila, Amgen Inc., Sandoz (a Novartis division), Aceto Corporation, Fresenius Kabi AG |
| SEGMENTS COVERED |
By Formulation Type - Tablets, Injectables, Oral Solutions
By End User - Hospitals, Clinics, Homecare Settings
By Indication - Schizophrenia, Bipolar Disorder, Major Depressive Disorder
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Quetiapine (CAS 111974-69-7) Market Dynamics
The Quetiapine (CAS 111974-69-7) Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Quetiapine (CAS 111974-69-7) Market Segmentations
Market Breakup by Formulation Type
- Overview
- Tablets
- Injectables
- Oral Solutions
Market Breakup by End User
- Overview
- Hospitals
- Clinics
- Homecare Settings
Market Breakup by Indication
- Overview
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Quetiapine (CAS 111974-69-7) Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- AstraZeneca
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries
- Mylan N.V.
- Hikma Pharmaceuticals
- Lupin Pharmaceuticals
- Zydus Cadila
- Amgen Inc.
- Sandoz (a Novartis division)
- Aceto Corporation
- Fresenius Kabi AG
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved